Sun Pharma: No India semaglutide sales until Novo Nordisk patent expires

• Sun Pharma will not sell semaglutide drugs in India until Novo Nordisk's patent expires in March 2026, following a Delhi High Court dispute.
• Sun Pharma will continue to export semaglutide products to markets where Novo Nordisk does not hold a patent.
• The Delhi High Court directed Sun Pharma to file a formal undertaking regarding its commitment.
• Novo Nordisk holds two key semaglutide patents, with the final one expiring in March 2026.
• The dispute is a closely watched legal tussle in India's pharmaceutical sector, with other companies also eyeing market entry post-2026.

Why It Matters: This patent battle delays access to cheaper diabetes/weight-loss drugs in India.